-

Scott+Scott Attorneys at Law LLP Reminds Investors of September 28 Deadline in Securities Class Action Against Ardelyx Inc. (NASDAQ: ARDX)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, reminds investors that a securities class action lawsuit has been filed against Ardelyx Inc. (NASDAQ: ARDX) (“Ardelyx” or the “Company”) and certain of its officers and directors, alleging violations of §§10(b) and 20(a) of the Securities Exchange Act (15 U.S.C. §78j(b) and §78t(a)) and Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b-5). If you purchased Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the “Class Period”), and have suffered a loss, realized or unrealized, you are encouraged to contact Jonathan Zimmerman for additional information at (888) 398-9312 or jzimmerman@scott-scott.com. The lead plaintiff deadline is September 28, 2021.

Ardelyx is focused on discovering, developing, and commercializing innovative medicines for patients suffering from kidney and cardiorenal diseases.

On July 19, 2021, the U.S. Food and Drug Administration (FDA) flagged deficiencies in Ardelyx’s New Drug Application of tenapanor, a novel product candidate to control serum phosphorus in adult patients with chronic kidney disease on dialysis. In the letter, the FDA noted that a key issue is the size of the treatment effect and its clinical relevance.

On this news, Ardelyx’s stock plummeted, falling from $7.70 per share on July 19, 2021, to close at $2.01 per share on July 20, 2021, a decline of nearly 74%.

The pending lawsuit alleges that, during the Class Period, Ardelyx and the other defendants made materially false and misleading and failed to disclose material facts about tenapanor and the likelihood that it would be approved by the FDA.

Lead Plaintiff Deadline

The Lead Plaintiff deadline in this action is September 28, 2021. Any member of the proposed Class may seek to serve as Lead Plaintiff through counsel of their choice, or may choose to do nothing and remain a member of the proposed Class.

What You Can Do

If you purchased Ardelyx securities between August 6, 2020 and July 19, 2021, or if you have questions about this notice or your legal rights, you are encouraged to contact attorney Jonathan Zimmerman at (888) 398-9312 or jzimmerman@scott-scott.com.

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.

This may be considered Attorney Advertising.

Contacts

Jonathan Zimmerman
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 17th Floor, New York, NY 10169
(888) 398-9312
jzimmerman@scott-scott.com

Scott+Scott Attorneys at Law LLP

NASDAQ:ARDX

Release Summary
Deadline Approaching in Ardelyx Securities Class Action - Investors Encouraged to Contact Scott+Scott
Release Versions
$Cashtags

Contacts

Jonathan Zimmerman
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 17th Floor, New York, NY 10169
(888) 398-9312
jzimmerman@scott-scott.com

More News From Scott+Scott Attorneys at Law LLP

DRAFTKINGS INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates DraftKings Inc.’s Directors and Officers for Breach of Fiduciary Duties – DKNG

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of DraftKings Inc. (NASDAQ: DKNG) failed to manage DraftKings in an acceptable manner, breaching their fiduciary duties to DraftKings, and whether DraftKings and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On December 8, 2023, consumers filed a lawsuit against...

JPMORGAN CHASE & CO. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates JPMorgan Chase & Co.’s Directors and Officers for Breach of Fiduciary Duties – JPM

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of JPMorgan Chase & Co. (NYSE: JPM) failed to manage JPMorgan Chase in an acceptable manner, breaching their fiduciary duties to JPMorgan Chase, and whether JPMorgan Chase and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 26, 2026, dozens of inst...

FIFTH THIRD BANCORP INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Fifth Third Bancorp’s Directors and Officers for Breach of Fiduciary Duties – FITB

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Fifth Third Bancorp (NASDAQ: FITB) failed to manage Fifth Third Bancorp in an acceptable manner, breaching their fiduciary duties to Fifth Third Bancorp, and whether Fifth Third Bancorp and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 26, 2026, d...
Back to Newsroom